Aspirin history and its clinical applications in pregnancy

Overview

This digest examines aspirin's pharmacological mechanisms and clinical applications in pregnancy, focusing on its irreversible inhibition of COX-1 and subsequent reduction of thromboxane A₂ production. The review synthesizes evidence regarding low-dose aspirin therapy for preventing hypertensive disorders in pregnancy, particularly preeclampsia, which represents a significant contributor to maternal and perinatal morbidity and mortality globally.

Methods and approach

The review integrates historical pharmaceutical development of aspirin with contemporary clinical evidence on low-dose aspirin administration in pregnancy. Evidence synthesis encompasses preeclampsia prevention protocols, timing of intervention initiation, comparative outcomes in specific high-risk populations including women with antiphospholipid syndrome and systemic lupus erythematosus, and combined therapeutic approaches using aspirin with heparin. Recommendations are assessed from major international clinical guideline bodies.

Key Findings

Low-dose aspirin demonstrates substantial efficacy in reducing preeclampsia incidence when initiated before 16 weeks gestation. Evidence demonstrates reductions in maternal and perinatal morbidity outcomes. Secondary benefits include decreased preterm birth rates and improved fetal growth parameters in selected intrauterine growth restriction cases. Combination therapy with heparin enhances pregnancy outcomes in women with antiphospholipid syndrome and systemic lupus erythematosus. International guidelines from ACOG, NICE, RCOG, WHO, and FIGO provide consistent support for low-dose aspirin use in identified high-risk pregnancy populations.

Implications

Low-dose aspirin represents an evidence-supported pharmacological intervention for hypertensive disorder prevention in high-risk pregnancies, with documented reductions in significant maternal and perinatal adverse outcomes. The sustained antiplatelet mechanism via COX-1 inhibition provides a clear mechanistic basis for therapeutic application in disorders involving platelet dysfunction and vascular pathology. Implementation across diverse healthcare systems benefits from strong concordance among international clinical guidelines, facilitating standardized protocols and risk stratification approaches.